https://biopharmaperspective.com/2026/10/09/bristol-myers-squibbs-zenbexus-cuts-progression-or-death-risk-by-51-in-phase-3-trial/ 2026-10-09T06:35:14Z Biopharma Perspective en Bristol Myers Squibb’s Zenbexus Cuts Progression or Death Risk by 51% in Phase 3 Trial 2026-10-09T06:35:12Z Blog https://biopharmaperspective.com/2026/10/08/cerevance-solengepras-meets-phase-3-endpoint-in-parkinsons-disease/ 2026-10-08T03:42:58Z Biopharma Perspective en Cerevance Solengepras Meets Phase 3 Endpoint in Parkinson’s Disease 2026-10-08T03:42:57Z Blog